Display options
Cite
Nemejcova K, Kocian R, Kohler C, et al. Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). Cancers (Basel). 2020;12(5)doi: 10.3390/cancers12051115.
Nemejcova, K., Kocian, R., Kohler, C., Jarkovsky, J., Klat, J., Berjon, A., Pilka, R., Sehnal, B., Gil-Ibanez, B., Lupo, E., Petiz, A., Sanchez, O. A., Kascak, P., Martinelli, F., Buda, A., Presl, J., Barahona, M., Lonkhuijzen, L. V., Szatkowski, W., Minar, L., Pakiz, M., Havelka, P., Zorrero, C., Misiek, M., Snyman, L. C., Wydra, D., Vergote, I., Vinnytska, A., Redecha, M., Michal, M., Tingulstad, S., Kipp, B., Szewczyk, G., Toth, R., Garcia, F. J. S., Martin, P. J. C., Poka, R., Tamussino, K., Luyckx, M., Fastrez, M., Staringer, J. C., Germanova, A., Plaikner, A., Bajsova, S., Dundr, P., Mallmann-Gottschalk, N., & Cibula, D. (2020). Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). Cancers, 12(5), . https://doi.org/10.3390/cancers12051115
Nemejcova, Kristyna, et al. "Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)." Cancers vol. 12,5 (2020). doi: https://doi.org/10.3390/cancers12051115
Nemejcova K, Kocian R, Kohler C, Jarkovsky J, Klat J, Berjon A, Pilka R, Sehnal B, Gil-Ibanez B, Lupo E, Petiz A, Sanchez OA, Kascak P, Martinelli F, Buda A, Presl J, Barahona M, Lonkhuijzen LV, Szatkowski W, Minar L, Pakiz M, Havelka P, Zorrero C, Misiek M, Snyman LC, Wydra D, Vergote I, Vinnytska A, Redecha M, Michal M, Tingulstad S, Kipp B, Szewczyk G, Toth R, Garcia FJS, Martin PJC, Poka R, Tamussino K, Luyckx M, Fastrez M, Staringer JC, Germanova A, Plaikner A, Bajsova S, Dundr P, Mallmann-Gottschalk N, Cibula D. Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). Cancers (Basel). 2020 Apr 29;12(5). doi: 10.3390/cancers12051115. PMID: 32365651; PMCID: PMC7281480.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Apr 29;12(5). doi: 10.3390/cancers12051115.

Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2).

Cancers

Kristyna Nemejcova, Roman Kocian, Christhardt Kohler, Jiri Jarkovsky, Jaroslav Klat, Alberto Berjon, Radovan Pilka, Borek Sehnal, Blanca Gil-Ibanez, Ezequiel Lupo, Almerinda Petiz, Octavio Arencibia Sanchez, Peter Kascak, Fabio Martinelli, Alessandro Buda, Jiri Presl, Marc Barahona, Luc van Lonkhuijzen, Wiktor Szatkowski, Lubos Minar, Maja Pakiz, Pavel Havelka, Cristina Zorrero, Marcin Misiek, Leon Cornelius Snyman, Dariusz Wydra, Ignace Vergote, Alla Vinnytska, Mikulas Redecha, Martin Michal, Solveig Tingulstad, Barbara Kipp, Grzegorz Szewczyk, Robert Toth, Francisco Javier de Santiago Garcia, Pluvio Jesus Coronado Martin, Robert Poka, Karl Tamussino, Mathieu Luyckx, Maxime Fastrez, Juan Carlos Staringer, Anna Germanova, Andrea Plaikner, Sylva Bajsova, Pavel Dundr, Nina Mallmann-Gottschalk, David Cibula

Affiliations

  1. Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic.
  2. Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000 Prague, Czech Republic.
  3. Department of Special Operative and Oncologic Gynaecology, Asklepios-Clinic Hamburg, 22763 Hamburg, Germany.
  4. Institute for Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.
  5. Department of Obstetrics and Gynecology, University Hospital Ostrava, 708 52 Ostrava Poruba, Czech Republic.
  6. Department of Pathology, La Paz University Hospital, 28046 Madrid, Spain.
  7. Molecular Pathology and Therapeutic Targets Group, IdiPAZ, 28046 Madrid, Spain.
  8. Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, 77520 Olomouc, Czech Republic.
  9. Department of Obstetrics and Gynecology, Bulovka Hospital, First Faculty of Medicine, Charles University, 18081 Prague, Czech Republic.
  10. Unit of Gynecological Oncology, Institute Clinic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  11. Department of Pathology, Institute of Oncology Angel H. Roffo, University of Buenos Aires, Buenos Aires Autonomous City 1214, Argentina.
  12. Department of Gynecology, Francisco Gentil Portuguese Oncology Institute, 4200-072 Porto, Portugal.
  13. Departments of Gynecologic Oncology, University Hospital of the Canary Islands, 35016 Las Palmas de Gran Canaria, Spain.
  14. Department of Obstetrics and Gynecology, Faculty Hospital Trencin, 91171 Trencin, Slovakia.
  15. IRCCS Foundation National Cancer Institute in Milan, 20133 Milan, Italy.
  16. Department of Obstetrics and Gynecology, Unit of Gynecologic Oncology Surgery, San Gerardo Hospital, 20900 Monza, Italy.
  17. Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, 30460 Prague, Czech Republic.
  18. Department of Gynecology, University Hospital of Bellvitge, Biomedical Research Institute of Bellvitge, University of Barcelona, 08907 Barcelona, Spain.
  19. Center for Gynecologic Oncology, Academic Medical Centre, 1100DD Amsterdam, The Netherlands.
  20. Department of Gynecologic Oncology, Centre of Oncology, M. Sklodowska-Curie Memorial Institute, Cracow Department, 31-115 Cracow, Poland.
  21. Department of Gynecology and Obstetrics, Faculty of Medicine, Masaryk University, 60200 Brno, Czech Republic.
  22. University Clinic for Gynaecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia.
  23. KNTB a.s, 762 75 Zlin, Czech Republic.
  24. Gynecology Department, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain.
  25. Department of Gynecologic Oncology, Holycross Cancer Center, 25-734 Kielce, Poland.
  26. Gynaecologic Oncology Unit, Department of Obstetrics and Gynaecology, University of Pretoria, Pretoria 0001, South Africa.
  27. Department of Gynecology, Gynecologic Oncology and Gynecologic Endocrinology, Medical University of 80-402 Gdansk, Poland.
  28. Department of Gynecology and Obstetrics, University Hospital Leuven, Leuven Cancer Institute, 3000 Leuven, Belgium.
  29. LISOD - Israeli Oncological Hospital, 08720 Plyuty, Ukraine.
  30. Department of Gynaecology and Obstetrics, University Hospital, Comenius University, 82101 Bratislava, Slovakia.
  31. Department of Obstetrics and Gynaecology, Hospital Ceske Budejovice, JSC, 37001 Ceske Budejovice, Czech Republic.
  32. Department of Gynaecology, St Olav's Hospital, 7006 Trondheim, Norway.
  33. Department of Obstetrics and Gynecology, Cantonal Hospital of Lucerne, 6000 Lucerne, Switzerland.
  34. Department of Obstetrics and Gynecology, Institute of Mother and Child, 01-211 Warsaw, Poland.
  35. Oncology Institute of East Slovakia, 04191 Košice, Slovakia.
  36. MD Anderson Cancer Center, 28033 Madrid, Spain.
  37. Department of Gynecology and Obstetrics, Hospital Clinico San Carlos, 28040 Madrid, Spain.
  38. Institute of Obstetrics and Gynaecology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
  39. Medical University of Graz, 8036 Graz, Austria.
  40. Department of Gynecology, Universite catholique de Louvain, Cliniques Universitaires St Luc, 1200 Brussels, Belgium.
  41. Department of Obstetrics and Gynaecology, St Pierre University Hospital, Universite Libre de Bruxelles, 1000 Brussels, Belgium.
  42. Department of Gynecology and Obstetrics, Hospital Español de Buenos Aires, Buenos Aires 2975, Argentina.
  43. Department of Gynecology, Medical Faculty, University of Cologne, 50937 Cologne, Germany.

PMID: 32365651 PMCID: PMC7281480 DOI: 10.3390/cancers12051115

Abstract

The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review.

Keywords: cervical cancer; metastases; sentinel lymph node

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the dec

References

  1. Gynecol Oncol. 2020 Feb;156(2):335-340 - PubMed
  2. Gynecol Oncol. 2007 Apr;105(1):189-93 - PubMed
  3. J Clin Oncol. 2011 May 1;29(13):1686-91 - PubMed
  4. Gynecol Oncol. 2004 May;93(2):458-64 - PubMed
  5. Int J Gynaecol Obstet. 2014 May;125(2):97-8 - PubMed
  6. Ann Surg Oncol. 2017 Aug;24(8):2311-2318 - PubMed
  7. Gynecol Oncol. 2015 May;137(2):291-8 - PubMed
  8. Gynecol Oncol. 2012 Dec;127(3):462-6 - PubMed
  9. Fertil Steril. 2020 Apr;113(4):685-703 - PubMed
  10. Gynecol Oncol. 2006 Nov;103(2):649-53 - PubMed
  11. Int J Gynecol Cancer. 2018 May;28(4):757-763 - PubMed
  12. Eur J Obstet Gynecol Reprod Biol. 2019 Oct;241:71-76 - PubMed
  13. Gynecol Oncol. 2019 Jan;152(1):202-207 - PubMed
  14. J Reprod Infertil. 2017 Apr-Jun;18(2):261-263 - PubMed
  15. J Cancer. 2018 Oct 10;9(21):3923-3928 - PubMed
  16. Ann Surg Oncol. 2016 Sep;23(9):2959-65 - PubMed
  17. Expert Rev Anticancer Ther. 2014 Mar;14(3):307-17 - PubMed
  18. Med Oncol. 2015 Jan;32(1):385 - PubMed
  19. Gynecol Oncol. 2014 May;133(2):274-7 - PubMed
  20. Int J Gynecol Cancer. 2015 Mar;25(3):521-5 - PubMed
  21. Gynecol Oncol. 2017 Mar;144(3):536-540 - PubMed
  22. Int J Gynecol Cancer. 2015 May;25(4):751-7 - PubMed
  23. J Psychosom Obstet Gynaecol. 2020 Jun;41(2):86-92 - PubMed
  24. Gynecol Oncol. 1990 Sep;38(3):352-7 - PubMed
  25. Int J Gynecol Cancer. 2013 Jan;23(1):157-63 - PubMed
  26. Gynecol Oncol. 2015 Dec;139(3):559-67 - PubMed
  27. Surg Oncol. 2008 Sep;17(3):227-35 - PubMed
  28. Arch Pathol Lab Med. 2019 Dec 23;: - PubMed
  29. Gynecol Oncol. 2012 Mar;124(3):496-501 - PubMed
  30. Int J Gynecol Cancer. 2018 May;28(4):641-655 - PubMed
  31. Gynecol Oncol. 2017 Apr;145(1):96-101 - PubMed
  32. Int J Gynecol Cancer. 2010 Apr;20(3):476-8 - PubMed
  33. Int J Gynecol Cancer. 2019 Jan;29(1):212-215 - PubMed
  34. Eur J Surg Oncol. 2015 Jan;41(1):1-20 - PubMed

Publication Types

Grant support